Melanotan I, also known as Afamelanotide, is a linear peptide composed of 13 amino acids that is poised to play an increasingly significant role in pharmaceutical research. As a revolutionary peptide drug, its precision synthesis process overcomes traditional limitations; every step-from resin selection to high-efficiency purification-determines the final purity and therapeutic efficacy, offering new hope for the treatment of photosensitivity disorders.
Melanotan I (also known as Afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) used to treat photosensitivity disorders associated with erythropoietic protoporphyria; currently, most Melanotan I products are labeled for research use only and are not intended for human use. In traditional solid-phase synthesis, the choice of resin significantly impacts the product's coupling efficiency and final purity.